Author Archives: admin


MHRA Unveils ‘Regulatory Ready’ Stem Cell Lines – Regulatory Focus

MHRA Unveils 'Regulatory Ready' Stem Cell Lines Posted 27 February 2017 By Michael Mezher

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) on Monday said it is looking to boost the development of cell therapies through the availability of what it calls "regulatory ready" embryonic stem cell lines.

"The UK Stem Cell Bank (UKSCB) at the National Institute for Biological Standards and Control (NIBSC) is releasing its first stem cell lines suitable for development into novel cell-based medicines to researchers wishing to bring new and innovative therapies to clinical trial," MHRA said on Monday.

The stem cell lines are intended to serve as qualified starting materials for cell therapies looking to enter clinical trials.

"The availability of EUTCD [EU Tissue and Cell Directives]-grade human embryonic stem cell lines via the UKSCB provides an invaluable 'gold standard' starting material; ensuring high quality and ethically-sourced stem cells are widely available to the research community to use in human clinical studies," said Rob Buckle, chief science officer at the UK's Medical Research Council, which is a co-sponsor of the UKSCB.

The stem cell lines will be produced by a handful of UK-based universities and deposited at the UKSCB in compliance with the EUTCD, which establishes quality and safety standards for human tissue and cells.

According to the UKSCB, "EUTCD-grade cell lines undergo a process known as due diligence to ensure they meet the requirements of the EU Tissue and Cell Directives before they are accepted for banking and distribution for human application. The EUTCD-grade cell lines have been derived from embryos under the informed consent requirements of the UK Fertilisation and Embryology Authority (HFEA) and have been reviewed by an independent UK Steering Committee."

In the coming months, MHRA says that stem cell lines produced by the University of Sheffield, University of Manchester and King's College London will be made available, followed by additional stem cell lines from Newcastle University and Roslin Cells by the end of the year.

MHRA

Share this article:

Categories: Human cell and tissue, Clinical, News, Europe, MHRA

Tags:

Link:
MHRA Unveils 'Regulatory Ready' Stem Cell Lines - Regulatory Focus

Dying to live (A young woman with a rare disease pushes to find a cure) – Rio Rancho Observer

A thin-green, extra-long oxygen tube bends and swirls across the tile floor of a kitchen in one nondescript Rio Rancho home.

On one end of the tube is a giant collection of heavy oxygen tanks lined up by the front door. On the other end gasping for her next breath is 25-year-old Anna Wenger.

Wenger has Systemic Diffuse Scleroderma, a rare disease that affects the skin, organs and immune system.

Its an auto-immune illness and theres two different kinds, Wenger said expertly. One is the diffuse and theres the limited; the diffuse is the worst kind because it hits your organs and limited just means its on the outside.

According to Wenger, this disease causes the body to produces too much collagen, which tightens the skin on the outside of many external body parts. Diffuse means the disease tightens the organs causing many internal health problems.

My lungs and all of my arteries are hardening, Wenger said. For a while, I was only experiencing the external symptoms, but when I turned 22 it started hurting me internally.

Wenger said this disease affects around 300,000 people nationwide and, of those diagnosed, many only have the external or limited symptoms.

Before Wengers diagnosis, she says she was an active child who enjoyed swimming, cheerleading, and playing soccer.

We would go to the lake every weekend and I had just started roller-blading, Wenger said. All of a sudden I lost a dramatic amount of weight, and started slowing down. I didnt notice it but those around me noticed it and thats when I went to the doctor.

Doctors diagnosed Wenger with Systemic Diffuse Scleroderma at 12 years of age, and told her mother she wouldnt live past 20. But Wenger said she didnt feel much different until a year later, when she noticed ulcers forming on her elbows.

Because of the rapid movement of the disease I lost some of my fingers and toes, Wenger said. The doctors gave me prednisone and methotrexate, which just wasnt helping.

Going to school became almost impossible at this point in her life, she said. After dropping out of school and trying to take her medication, Wenger noticed she was rapidly getting worse.

After 10 years of external symptoms only, it started hitting my organs really bad, Wenger said.

She was living on her own in Arizona dealing with her symptoms, she said, when everything changed.

I was happy I had outlived the date doctors said I would die, when I became so ill I had to move to New Mexico to receive help from my mom, Wenger said.

One day, after moving in with her mother, Wenger said she felt really cold and could not breathe very well.

We went to the hospital and they put me on oxygen, then I got really hungry and ate some (fast food) and went into heart failure, Wenger said. Then I had to be incubated and woke up five days later on life support and 33 liters of oxygen.

Every day has been different for Wenger since that fateful incident, she said. Now Wenger has to prepare a specific low sodium diet from scratch on a regular basis that does not interfere with her symptoms. Wenger also has to be hooked up to oxygen everywhere she goes to compensate for her lung functions due to the reaction of her disease.

Although many people would be devastated by this sudden lifestyle change, Wenger stays optimistic, because she says she knows of a possible cure.

With a stem cell transplant, doctors take out your stem cells, and then they harvest them to get them healthier, Wenger said. Then you go through five days of intense chemotherapy and then they put the cells back into your body to re-start your immune system.

The cost of the procedure that may cure Wenger is $150,000, plus an additional $25,000 for the evaluations from a specialist, she said.

Thats not even including lodging and food and everything else, Wenger said.

This procedure, which is still in trial, is not covered by Medicare, she said. Add in the fact that Wenger has heart issues puts her at-risk for many of the clinics providing stem cell replacement.

Stretching resources is a daily battle for Wenger, who lives on $700 a month, she said.

If I hadnt moved in with my mom, there is no way I would make it through, Wenger said.

Theresa Johnson, Wengers mother and main caregiver, said she fell to the ground after hearing her daughters initial diagnosis.

I really had a hard time getting my head around it, Johnson said. At that time, when she was 12, she was barely walking because the symptoms got so bad.

Johnson said her daughter was a natural competitor that excelled in sports and loved dancing.

When this disease hit her body, it hit her skin very rapidly and she tightened up and could not move. Johnson said. For a long time the disease stopped at her skin and did not go into her organs, so we were hopeful.

Now, with full understanding of the seriousness of her daughters disease, Johnson said she is looking for ways to help find a cure.

Sacrifice is the main thing, Johnson said. I dont want anything for myself everything is for her and my son. I will do anything to see her get better. If I have to lose my home I will lose it whatever.

Although Wenger is limited on her mobility, she said she likes to stay busy and active working on many projects.

I like a lot of different things. I like to put together furniture, I love painting and thats pretty cool that I can still do it even though half my right hand is missing, she said, laughing at that.

Wenger has also put together a Scleroderma support group that meets the second Saturday of every month at Sabana Grande Recreation Center, just down the street from her home.

I had 15 people meet up at my last support group, Wenger said. I am the main person who does this, but the people help me put up the chairs.

Family members and people dealing with Scleroderma are in attendance, she said.

I love doing this; it makes me feel good and all of the members are so sweet to me, Wenger said.

Wenger kept her diagnosis a secret for a long time because she was afraid people would treat her differently, she said.

I just wanted to be a normal teenager, Wenger said. Now that I look back, I shouldve raised awareness of my disease to help others with the same symptoms out, thats what I am doing now.

Wenger said she feels blessed to still be able to do things because she knows of so many with the disease that cant.

I can still make my own food, change my clothes, take a shower and do daily tasks, Wenger said. I still count my blessings.

Read the rest here:
Dying to live (A young woman with a rare disease pushes to find a cure) - Rio Rancho Observer

Luciano: When nursing home says hit the road, what if you can’t walk? – Peoria Journal Star

Phil Luciano Journal Star columnist @lucianophil

WASHINGTON Like many 16-year-olds, Jason Hermacinski insists he knows whats best for himself.

From his long-term-care room at Washington Christian Village, he demands, I want to go home. I dont see any reason why I cant.

But Jason isnt 16. He just thinks that way. He is actually 37 yet will always have the mind of a teen.

Thats because of adrenoleukodystrophy, or ALD, a brutal genetic disease that also has killed all sensation below his waist.

Doctors say he needs specialized care 24-7. He gets the care he needs at Washington Christian Village. But the center is trying to give him the boot, in what it calls an effort to help Jason.

His parents and doctors oppose the move. If they lose the fight, his parents fear what will become of Jason.

Hes lost everything in his life, his mom says.

***

Clark and Linda Smith sweat through their golden years.

The widower and widow wed 23 years ago. He's had surgery for lung cancer. She's had two pacemakers. In 2013, their Washington home was obliterated by a tornado.

But no challenge has been as hard as their fight regarding ALD. He is 80, she soon will turn 70.

I dont know how much more time we have to fight for Jason, Clark Smith says.

The struggles of ALD caught Hollywood's eye with 1992's Lorenzos Oil, which spotlighted two real-life parents seeking help for their afflicted son. According to the not-for-profit Stop ALD Foundation, the disease affects one in 18,000 people. It destroys myelin, the protective sheath around the brain's neurons, which allow people to think and to control muscles.

ALD is caused by a genetic abnormality in the X chromosome: its carried only by females. ALD symptoms in females are rare and mild. But in men, severe physical and brain deterioration can result, starting in childhood or beyond.

There are two treatments. Lorenzos oil combines fats from olive and rapeseed oils. In boys, it shows indications of staving off the onset of symptoms.

After a patient becomes symptomatic, the other treatment is a stem-cell transplant. Doctors believe the new cells share a missing ALD protein in the brain and halt brain damage.

ALD and other maladies haunt Jasons family, beyond his mom and stepdad. When Jason was 12, cancer took his dad. Just before that, Jason was tested for ALD, as his two brothers (older by nine and 12 years) had shown its traits. Each brother is married with a family. One still works; the other is disabled.

Jason seems to have gotten it the worst," his stepfather says.

For more than 20 years, Jason has been under the care of local doctors, plus ALD experts in Minnesota. Years back, a regimen of Lorenzo's oil possibly slowed his ALD. At age 24, Jason became a father, as well as sole caregiver for the boy, his parents say. Around that time, he began experiencing symptoms of ALD, including lesions on lower extremities. He gradually lost mobility in his legs, along with the ability to hold a job.

For years, he and his son lived in a trailer in East Peoria. But ALD started to degrade Jason's brain, and last year his Minnesota ALD experts advised a bone-marrow implant. The surgery was a success in ceasing further brain erosion.

But recovery was difficult, hampered by severe lesion infection. After rehab in Minnesota, he continued recovery at the home of his parents. But soon they realized they could not offer proper care. If he tumbles over, they have a hard time lifting him. With no sensation below the waist, he is unable to control his bladder or bowels, meaning he needs frequent cleaning. Meanwhile, lesions and infections are relentless and serious, with some near his spine, so he needs repeated wound care every day. Plus, he takes 25 medicines a day.

Last summer, that swirl of complications meant 10 trips to emergency rooms.

That summer was a nightmare, Clark Smith says.

***

If infection is kept in check, Jason could live a normal lifespan. But, doctors say, he always will need to be in long-term care, especially for wound care. The state has told Jason and his parents that his needs exceed the parameters of the cost and expectations of in-home aides, which his parents can't afford to cover themselves. Thus, he almost certainly will spend the rest of his life in a care facility.

He doesn't like that notion, regardless of medical logic. ALD has reduced his brain his thinking, his attitude to the mindset of a 16 year old, forever. Mood swings are teen-like: amiable one moment, vindictive the next.

He thinks he knows everything, his mom says. Everyone is wrong. The doctors dont know anything. Were ruining his life. Yada, yada, yada.

With legal guardianship over Jason, his parents in October took him to live at Washington Christian Village, walking distance from their home. They visit daily and often take him offsite for medical and social visits. Meanwhile, Jason's son (who has been staying with a family friend) visits regularly, as do Jasons pals. They sometimes bring by Jasons beloved dog, Wolfie, a 13-year-old Lab mutt.

Otherwise, Jason spends most of his time in his room, watching TV and texting friends just like many teens. Still, he is adamant about getting back home to the old trailer and his son.

During a visit by me, he didnt complain much about Washington Christian Village.

Its OK, he said with shrug. Theres a lot of old people. He admits to having trouble relating to seniors, joking sarcastically, I dont remember anything about World War II.

But to his parents, he always has protested living there. Sometimes he lashes out at his mom, blaming her for his predicament. But he doesnt berate other residents or otherwise cause problems.

Meanwhile, he has learned how to cause a ruckus with staff.

Weeks ago, hospital staffers talked to him about long-term needs, saying he would need lifelong, long-term care. He impulsively blurted, Id rather die. That prompted a notification to the administration, plus a ride to the emergency room.

Doctors quickly deemed him not a threat and sent him back to Washington Christian Village. But, a quick learner, Jason on two other occasions mentioned suicide, as a way to vent his frustration and provoke staff.

His stepfather says, He doesn't know how to express himself (appropriately). But hes learned that saying suicide gets attention.

It also got him an involuntary discharge. State and federal laws allow nursing-home discharges only for a handful of reasons, one of which was cited by Washington Christian Village: Your welfare and needs cannot be met by this facility. To his parents, staff said he needs mental-health counseling regarding possible suicide.

His parents replied to the administration by saying counseling cant repair Jasons brain: ALD has caused permanent damage, akin to dementia. Further, they have provided him off-site counseling, about every two weeks.

Moreover, letters from Jasons ALD experts say Jason isnt serious about suicide. Dr. Gerald Raymond, a renowned authority on ALD, as well as Jasons primary neurologist for more than 20 years, states, He is known to be brain-injured and impulsive and often makes irrational statements. But he has not been judged to be an active risk for suicide by multiple providers. These statements that he will self-harm do not justify the abandonment of care by the facility.

***

Right after issuing the discharge, Washington Christian Village assisted his parents in contacting more than three-dozen facilities within 35 miles of Washington. A few didnt respond. But the rest said they were full, had a long wait list or didnt meet Jasons needs.

Of possible note, the destitute Jason depends on Medicaid. The state has a massive backlog of Medicaid payments, some 18 months long, which can be tough on a providers bottom line. No law forces a facility to accept a patient.

Washington Christian Village found one welcoming place for Jason: Roseville Rehabilitation & Health Care. His parents toured the place and found it nice. However, Roseville does not have severe-wound care. And its lone psychiatrist visits just once every three months.

Plus, its 75 miles away. Jason essentially would be on his own, with rare visitors. And his Peoria medical providers would be too far away.

All that considered, his parents cant understand why Washington Christian Village would suggest Roseville. Nor can his ALD experts, including Dr. Raymond, who wrote about Jason: His care should be provided in a skilled nursing facility that is located close enough to his guardian but also allow access for his son and other family members to visit.

The discharge threatens to drop off Jason at his parents home. But the discharge is now in abeyance, as his parents have filed an appeal. Arguments by an attorney for Washington Christian Village and an attorney hired by Jasons parents will be offered March 2 before a hearing officer with the Illinois Department of Public Health, which oversees nursing homes. Days or weeks later, the officer will forward a recommendation to the agency director, who will issue a formal ruling.

Clark and Linda Smith have spoken and written to the facilitys corporate owner, Christian Horizons, which operates nursing homes in four states. Jake Bell, CEO for Christian Horizons, declined to comment for this story, citing patient confidentiality.

Beyond the appeal ruling, Jasons parents realize he likely will outlive them. Who will become his guardian? Who will look after his best interests?

Clark Smith sighs with the weight of all of his 80 years. Then says, We dont know. Were just trying to get past this emergency."

PHIL LUCIANO is a Journal Star columnist. He can be reached at pluciano@pjstar.com, facebook.com/philluciano and (309) 686-3155. Follow him on Twitter.com/LucianoPhil.

Read more:
Luciano: When nursing home says hit the road, what if you can't walk? - Peoria Journal Star

Study of SanBio’s Stem Cell Treatment for Stroke Receives Innovation Award from American Heart Association – Yahoo Finance

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--

SanBio, Inc., a scientific leader in regenerative medicine for neurological disorders, today announced that a recent publication of its novel stem cell treatment, SB623, for patients following a stroke, has received a prestigious award from the American Heart Association. The scientific article, Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study, was the third prize winner of the 2016 Stroke Progress and Innovation Award.

The Progress and Innovation Awards are offered by Stroke, a leading scientific journal addressing the diagnosis and treatment of cerebrovascular diseases, jointly with the American Heart Association and American Stroke Association. Previous award winners have established important standards of care in neurology, including Activase (alteplase) and induced hypothermia treatment.

Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, said, This prize from the American Heart Association recognizes the innovation of our stem cell treatment, SB623, and its potential to treat patients suffering from chronic physical impairments following ischemic stroke. The results of this study are encouraging to all those suffering from the long-term effects of stroke as well as the medical community working to advance treatment options.

The clinical trial was a Phase 1/2a, open-label, single-arm, dose escalation study of 18 patients with chronic motor deficits present for at least six months following an ischemic stroke. Patients received precisely targeted injections of SB623 cells directly into the neural tissue surrounding the damaged area of the brain.

Dr. Gary Steinberg, Chairman of the Department of Neurosurgery at the Stanford University School of Medicine and Co-Director of the Stanford Stroke Center, served as Principal Investigator for the clinical trial.

Results for subjects who completed the single arm Phase 1/2a study demonstrated statistically significant improvement in motor function, evaluated using the European Stroke Scale, National Institutes of Health Stroke Scale, the Fugl-Meyer total score and the Fugl-Meyer motor function total score. The data also showed that the treatment was generally safe and well-tolerated by the trial participants.

As lead author of the scientific article, Dr. Steinberg accepted the award at the recent International Stroke Conference in Houston.

About SanBio, Inc. (SanBio)

SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke, with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial using SB623 in the United States and Japan for the treatment of motor impairment resulting from traumatic brain injury. More information about SanBio is available at http://www.sanbio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170226005250/en/

See the rest here:
Study of SanBio's Stem Cell Treatment for Stroke Receives Innovation Award from American Heart Association - Yahoo Finance

World-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board – P&T Community

World-Renowned Stem Cell Transplantation Expert joins Cellect's Advisory Board
P&T Community
"Dr. Cutler is world renowned for his contributions to innovations within the stem cell transplantation industry to drive potential treatments in cancer and many other medical conditions, said Dr. Shai Yarkoni, Cellect's CEO. We look forward to ...

and more »

Here is the original post:
World-Renowned Stem Cell Transplantation Expert joins Cellect's Advisory Board - P&T Community

SA-Based INCELL’s Innovation to Fuel Biomanufacturing Market – Rivard Report

Business & Tech By Iris Gonzalez | 6 hours ago

Scott Ball / Rivard Report

Scientists work in the product formulation room which is part of the biomanufacturing suite at INCELL.

The United States is a leader in engineering biology research and supporting science and technology fields. However, both local and national markets need further investment to translate the development of these new tools into robust technologies that will support reproducible biomanufacturing.

With its unique business model and advanced research and technologies, San Antonio-basedbiomedical products manufacturer INCELL is on a mission to propel biomanufacturing in regenerative medicineforward.

Research in regenerative medicine requires specialized expertise, facilities, and sizable amounts of capital. Work on regenerative tissue engineering using molecular biology as the foundation for replacing, engineering, or regenerating human cells, tissues, or organs to restore or establish normal function also requires biotechnology manufacturing, a vital part of growing the biotech ecosystem that isnt discussed as much.

With attention focused on how advanced manufacturing is growing across industry sectors, the Rivard Report visitedINCELLs headquartersoff I-10 and DeZavalato learn more about the state of the biomanufacturing industry.

INCELL is a biomedicine products manufacturer and contract services provider, which manufactures and develops effective treatments for unmet medical needs conditions for which there exists no satisfactory method of diagnosis, prevention, or treatment.

Were at the precipice of total kick ass cell biotechnology, INCELL founder, Chief Science Officer, and CEO Dr. Mary Pat Moyer said.

Scott Ball / Rivard Report

Dr. Mary Pat Moyer is founder and chief science officer at INCELL.

A biomedical scientist, entrepreneur, and technology business leader with more than four decades of experience in business and science, Moyer was a professor of surgery but is not a surgeon. In 1981 she became the first female faculty member in the UT Health San Antonio Long School of Medicines department of surgery and their first Ph.D. (rather than an M.D.) professor.

Moyers path has been a nontraditional one, and it has served her well in the fields of regenerative medicine and infectious diseases. INCELLs main business units are in cell and tissue therapies as well as vaccines and infectious diseases.

Things have changed so much, as in the tools and the science, especially the cell biology and genetics, Moyer said. I started out as a basic scientist, trained in microbiology and molecular virology. A virologist has to know cells well because viruses are intracellular parasites.

Moyer brought that cellular knowledge to the medical schools surgery department, where she was hired to create research in the department. Moyer developed her knowledge base in what is now known as regenerative medicine cell, tissue, and gene technologies, tools, and therapies.

Since Moyer founded INCELL in 1993, the company has developed unique formulas of manufactured sterile media and cell culture products which have been shipped worldwide over the past 10-12 years. This includes two unique INCELL human colon cell lines licensed for research use in cancer, nutrition, environmental, and cell biology studies. INCELL also does contract services for the development, manufacturing, research, and testing of cells, tissues, vaccines, and solutions, thus helping many biotech companies globally.

The media solutions and reagents are part of human tissue bioprocessing used either as direct products or grown as replicating cell cultures which INCELL cryostores in suspended amination. Scientists and doctors use these stored tissues, stem cells, and functional cells to help patients suffering from arthritis, cancer, neural degeneration, cardiovascular diseases, and damaged tissues needing renewal and repair, to name a few applications.

The pathway from concept to patient use requires biomanufacuturing, which INCELL specializes in.

Moyer sees a gap in scientists and the publics knowledge when it comes to commercializing a medical product. It takes more than a good idea and money; an educated workforce, sustained funding streams, quality product manufacturing, and an understanding of the market are also essential.

When people talk about [taking an idea from] bench to bedside, theres typically no mention of manufacturing, Moyer explained. People may think manufacturing is blue collar, but its critical in order to get anything to the clinic when the patient can use the product.

INCELL, Moyer stressed, is a small biotech business, rather than a venture capital fueled company. It is difficult and takes longer to go this route, but Moyer has focused on building a strong foundation in a company with well-trained staff, quality contract services, and innovative biotech products for the clinical market.

You have to work out your basic manufacturing, product release, and safety protocols scientists typically dont have training [in]this aspect of commercialization, Moyer added. As a business owner I have to invest huge amounts of time and resources to train staff. Young people out of school and university labs may have a good knowledge of conceptual science and general procedures; however, they are inadequately prepared to work in their scientific discipline in industry.

INCELL wasbuilt as a collaborative industry-research-government-education biotech company business model with capital from product sales, competitive contracts, and government small business grants. It adopted a different business model for personalized stem cell medicines with collection and manufacturing kits for specific medical needs. INCELLson-site cryostorage facility uses itsworld-class solutions to store human cells and tissues intended for clinical use.

We cryostore tumor cells and blood cells from patients at our facility, Moyer said. We can grow those cells, and then work as part of a clinical discovery team with medical professionals, scientists, other labs, and patients to help determine if there are personalized therapies such as targeted drugs or vaccines for cancer or immunotherapies that could be developed to treat a specific patients disease.

However, Moyer decided a new collaborative team approach with multiple companies would lend itself bestto supporting the research, development, and commercialization of so many new and different therapies.

In 2016, Moyer set up the Foundation for Cell, Gene and Tissue Innovations (CGTI) as a nonprofit that participates in tissue or cell collections and accepts charitable donations for research, product development, and pre-clinical and clinical testing of manufactured products. Moyer also formed4RMED to oversee clinical trials and regulatory needs for CGTI, INCELL, and their clients. 4RMED oversees the human subjects research protocols, manages Investigational New Drug Applications (INDs) for drugs and biological products, and prepares documents in support of medical devices and combination products applications.

Our vision for personalized medicine is that we will have components ready to go on site at INCELL or on location with qualified hospital or clinical partners, Moyer explained. For a patient presenting with a targeted disease, INCELL or its collaborating clinical sites, could offer off-the-shelf processes, products, or participation in ongoing clinical studies for a faster response time.

With projects and products in the queue that address unmet medical needs and many targeted diseases, the cell therapy products will be commercialized by new spin-off companies funded through private and public investors and supported through INCELLs affiliated incubator company TEKSA Innovations Corp.

In June 2016, INCELL announced its new partnership with a Belgian investor group formed by Wisetree Invest and 4 for Cells, expected to fuel 50 new jobs at INCELLs headquarters in San Antonio over the short term. The resulting joint venture companyBioturnkeywill have a U.S. location in San Antonio and a site in Belgium.

Moyer opted for a collaborative partnership with INCELL and Bioturnkey working in both the U.S. and Europe. The parallel development of biotech products with coordinated manufacturing and commercialization in both markets would reduce delays, costs, and complications for new products entering the clinical markets in both places. By working in tandem, the partners can ensure products meet regulatory requirements so products are ready in about the same time frame in both markets.

The Bioturnkey businessplan is to accelerate developing personalized medicine and cell therapy products by linking INCELLs quality manufacturing technologies with closed bio-isolators and ready-to-go systems in Europe and the U.S. Moyer described this collaborative approach as a startup accelerator because the newly created companies can take advantage of manufacturing expertise and techniques already in place at INCELL and, therefore, get products to market faster.

According to Moyer, its an exciting time to be working at the forefront of regenerative medicine. It is my passion and my lifes work to see these products get to the clinic, shestressed.

The leveraged, collaborative support via CGTI, INCELL manufacturing and testing, 4RMED clinical trials, TEKSA incubation of new companies, and collaborative business initiatives with Bioturnkey and other entities in the U.S. and globally, should help catapult San Antonios growing regenerative medicine industry forward.

Iris Gonzalez is a contributing writer covering technology, life science, and veteran affairs for the Rivard Report. A first generation Cuban American, she is also a strategic planning consultant for nonprofit and government sectors and a docent at the San Antonio Museum of Art.

Go here to read the rest:
SA-Based INCELL's Innovation to Fuel Biomanufacturing Market - Rivard Report

‘Small Town Throwdown’ for Zach Standen on March 11 – The Redding Pilot

Bobby Paultauf and his band will play the throwdown.

Those in the Redding, Easton area are probably aware of what happened to Joel Barlow High School student Zach Standen in the summer of 2016. Zach was in a devastating auto accident that left him partially paralyzed.

He needs hope and support from as many people as possible. He needs countless medical procedures in order to gain movement to his legs again through stem cell treatment due to a tragic car accident that made him paralyzed.

To help support Standens recovery, local musicians Bobby Paltauf, of the Bobby Paltauf Band, and Grayson Hugh, of Grayson Hugh & the Moon Hawks, will play a benefit show on Saturday, March 11 at the Fairfield Theater Company.

The family has started a GoFundMe account where people are able to donate to this expensive treatment. Lets all get together and help him walk again, Paultaufs mother, Tiffany, wrote in a press release.

Bobby Paltauf is a senior at Joel Barlow High School, where Standen goes.

Lets all get together and support local live music, especially where it benefits the hope of Zach being able to walk again, his mother wrote.

For the concert benefitting Standen, more information can be found on The Bobby Paltauf Band page on Facebook, and tickets are available at http://www.fairfieldtheatre.org.

Zach Standen coached soccer Oct. 8 at Seaside Park in Bridgeport with, back row, left to right, Mark Roman, Alastair Bruce and Peter Syku.

Standen may be helped by stem cell medical treatments that can be administered in Panama.

The Standen family is in discussions and communication with the Cell Medicine Institute in that country and are pursuing this line of treatment for the young man, who is paralyzed.

We have done much research into stem cell therapy for spinal cord injuries here in the U.S. and Canada, and there just are no clinical trials or clinics that have the experience and track record like this one, the family said in a recent letter. Cell Medicine has been doing this specific treatment since 2006 and has a 60% to 70% success rate of some kind of improvements in most patients within a year.

Each procedure costs $37,200, which includes all medical procedures and ancillary needs. This is not covered by medical insurance.

The family is hoping everyone reading this could go to his GoFundMe page and donate $25, to help Zachs recovery.

To donate, visit: https://www.gofundme.com/stem-cell-therapy-for-zach-standen.

Continue reading here:
'Small Town Throwdown' for Zach Standen on March 11 - The Redding Pilot

Generous Teessiders fund mum’s 15000 trip to China for stem cell treatment – Gazette Live

A MUM has China in her sights thanks to the kindness of Tessiders.

The Gazette told last October how Teesville mum Jodie Hardwick, 29, was diagnosed with a muscle-wasting condition when she was 11 and has coped with life in a wheelchair - and deteriorating sight - ever since.

Her failing eyesight means she can only see children Rhys and Sian in silhouette - but pioneering stem cell surgery in China could change all that.

And thanks to the generosity of family, friends and many people she doesnt even know, shell be heading to the Far East in May.

With more than 12,000 of her 15,000 target raised, it means Jodie, mum Michelle and her aunty Julie Allport will be jetting out to Hong Kong at the end of May before travelling to the Shixin Hospital in Dongguan, on the Chinese mainland.

Its hoped the treatment she receives there, while not offering a cure for her Friedrichs Ataxia, could slow its progress and even bring back some of Jodies sight, hearing and muscle function.

Treatment on people with similar conditions has seen some improvement with their sight, speech and muscle control.

Its been a whirlwind few months of fundraising for the family - and theyre eager to say thanks to everyone who has helped.

Larger donations have included 2,500 from a fundraising night at the Dormans club in Middlesbrough, 1,000 from Blueline and Marton Taxis and 1,430 from two bucket collections at the Waterloo Road mosque in Middlesbrough.

The Club Bongo International, the Red Lion in Linthorpe and family and friends have also helped hugely with fundraising.

Mum Michelle said: Weve got most of the money in now - we just need that final push to reach the 15,000.

People have donated through the GoFundMe page but its mainly been through direct donations.

Its been unbelievable really, were so grateful. Jodies quiet astonished and excited - she didnt think it was going to happen.

Were flabbergasted at how generous people have been.

Visit http://www.gofundme.com/2tkcv4s.

Visit link:
Generous Teessiders fund mum's 15000 trip to China for stem cell treatment - Gazette Live

Steenblock Research Institute Announces New Method of Obtaining … – PRUnderground (press release)

The treatment of chronic diseases and medical conditions using a patients own stem cells is an exciting, dynamic area of medicine that is enjoying unprecedented success thanks to a combination of new discoveries and impressive patient responses. Here in the US, over 600 private clinics are doing stem cell therapies, most using stem cells taken from a patients own bone marrow or fat tissue.

Unfortunately, many ailing people are reluctant or unable to undergo the harvesting of bone marrow or fat tissue. With this in mind, physician David Steenblock, president of the nonprofit Steenblock Research Institute (SRI), asked the scientists at his research institute to come up with a way of getting enough stem cells from a patients blood sample to treat their health issues.

The scientists at SRI went on to develop an FDA compliant method for winding up with as many stem cells in 2 small tubes of blood (drawn from a patient) as are normally obtained from much larger quantities of bone marrow or fat tissue. The blood is exposed to heat, cold, light and electromagnetics which yields 100 million stem cells, an amount which is ten times the minimum of 10 million cells needed to produce a clinical response.

SRIs new method has beenauthorized for use byonly one clinic: Personalized Regenerative Medicine Clinic of San Clemente, California.

Adds Dr. Steenblock, Stem Cell Therapy is experimental and thus is not covered by any insurance plan. This new method is also only available to patients of Personalized Regenerative Medicine Clinic.

Those interested in learning more are invited to call Personalized Regenerative Medicine Clinic (PRMC) at 1-949-367-8870 from 9 am to 4 pm Pacific Time, Monday through Friday. Individuals who enroll as new patients are being offered an initial office visit for free with PRMCs Dr. Donna Hanna.

About David A. Steenblock, D.O., Inc.

Dr. David Steenblock and his Personalized Regenerative Medicine Clinic are both committed to and passionate about advancing medicine. They do this, in part, by creating customized treatment regimens for patients which often includes the use of stem cells and FDA approved stem cell mobilizers and activators. In addition, Dr. Steenblock brings to the table finely honed diagnostic skills as well as a wealth of knowledge, experience, and insight plus the courage to explore, experiment and innovate in a private clinical setting.

The rest is here:
Steenblock Research Institute Announces New Method of Obtaining ... - PRUnderground (press release)

20 Years After Dolly the Sheep, Potential of Cloning Remains Unclear – FOX40

(CNN) On February 22, 1997, the world learned about a secret project that scientists at the Roslin Institute in Scotland had been working on.

More than seven months earlier, on July 5, 1996, they had aided a Scottish Blackface sheep in giving birth to a Finn Dorset lamb codenamed 6LL3.

She was the first mammal to ever be cloned from the cells of an adult animal.

Using a breakthrough technique called somatic cell nuclear transfer, scientists at Roslin took a nucleus the part of the cell that contains most of its genetic information from cells within the mammary gland of an adult sheep and stuck it inside an unfertilized egg from which the nucleus had been removed.

EDINBURGH, SCOTLAND JULY 05: Sophie Goggins from the National Museums Scotland views Dolly the Sheep during the opening of a major new development at the National Museum of Scotland on July 5, 2016 in Edinburgh,Scotland. The National Museum of Scotland today opened ten new galleries devoted to science, art and design, as part of 14.1m project which increased its exhibition space by almost half and putting many treasures from its collections on display for the first time. (Photo by Jeff J Mitchell/Getty Images)

They stimulated the egg to develop into an embryo and planted the embryo into a surrogate mother. The lamb was dubbed Dolly, a nod to country music legend Dolly Parton and her famously ample bosom.

Years later, that same cell cluster was used to make four other sheep just like Dolly.

Revealing Dolly

The lab had kept her birth secret for seven months to make the announcement coincide with the publication of the scientific paper describing the experiments that produced her, they said.

That week, they recall, they received 3,000 phone calls from all over the world, according to the Roslin Institute.

Much of the news reports had focused not on cloning sheep but on its potential for humans, said Alan Colman, who is now a visiting scholar in the Harvard University Department of Stem Cell and Regenerative Biology.

At the time, Colman was research director at PPL Therapeutics, which specialized in producing transgenic (genetically engineered) livestock.

Wed underestimated the impact the announcement would make, he said. It was something we had prepared for, but we had been totally overwhelmed by the response.

Dollys legacy

Previously, cloning had been done using only embryonic cells, and now researchers had showed that it was possible in cells from another part of the body and adult body.

At the time she was born, I was ecstatic, because no one had previously been able to use nuclear transfer to make an adult vertebrate from an adult cell, Colman said.

Despite the headlines, cloning a mammal wasnt the teams main goal. They were out to develop a more efficient way to produce genetically modified livestock.

In fact, Dolly wasnt even the first to ever be cloned. She was the first mammal cloned from an adult cell.

But scientists have learned a lot since developing the technique, and somatic cell nuclear transfer has been used in more than 20 species to make clones.

The Roslin Institute explained that people have long been motivated to try cloning to make copies of the very best animals for agricultural purposes. Also, since the mid-1980s, there has been an interest in making new uses for farm animals, including producing human proteins in the milk of transgenic cows or sheep for medicinal use in humans.

South Koreas Sooam Biotech Research Foundation have even cloned dogs.

But by and large, scientists dont see a need to clone humans.

Instead, they are using what they learned from creating Dolly to make advancements in stem cell therapy, such as to create embryonic stem cells directly from a patients own cells. They can then study the progression of whichever disease the patient has.

Concerns

Dolly herself lived out her days at the Roslin Institute and was able to produce six lambs.

But she was euthanized at age 6 after being diagnosed with progressive lung disease and after a long battle with arthritis.

Finn Dorset sheep usually live 10 to 11 years, and her health problems seemed to confirm fears that cloned animals would age faster and die prematurely compared with animals born naturally.

This was further exemplified by Dollys four cloned sisters, who were recently euthanized because they too began to show symptoms of osteoarthritis.

OA, as you may know, is a progressive disease, and we took appropriate measures to manage the condition at the time under veterinary guidance, said Kevin Sinclair, a developmental biologist at the University of Nottingham who led research on the sheep.

These animals were in their 10th year and so coming towards the end of their natural lifespan.

A recent study of the remaining clones, however, found that they aged the same as naturally born sheep.

To investigate this further, the team at Nottingham will now conduct postmortem examinations to truly understand whats going on inside the animals.

The final phase of our study involves detailed postmortem analyses of different tissues and organs in order to gain a better insight into the aging process in these animals, Sinclair said.

The Roslin Institute donated Dollys body to the National Museum of Scotland, where she stands to this day.

View post:
20 Years After Dolly the Sheep, Potential of Cloning Remains Unclear - FOX40